Anti-IL-17 phase II data for psoriasis: A review

References

• Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14:485–96. PubMed PMID: 8818558
   PubMed Web of Science ®Google Scholar
• Arsiwala S. Infliximab: efficacy in psoriasis. Indian J Dermatol Venereol Leprol. 2013;79:S25–34. PubMed PMID: 23974692
   Google Scholar
• Novelli L, Chimenti MS, Chiricozzi A, Perricone R. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmunity reviews. 2014 Jan;13(1):64–9. PubMed PMID: 24021172
   Google Scholar
• Mitra A, Fallen RS, Lima HC. Cytokine-based therapy in psoriasis. Clin Rev Allergy Immunol. 2013;44:173–82. PubMed PMID: 22426927
   PubMed Web of Science ®Google Scholar
• Roark CL, Simonian PL, Fontenot AP, et al. Gammadelta T cells: an important source of IL-17. Curr Opin Immunol. 2008;20:353–7. PubMed PMID: 18439808. Pubmed Central PMCID: 2601685
   PubMed Web of Science ®Google Scholar
• Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res. 2007;17:435–40. PubMed PMID: 17452998
   PubMed Web of Science ®Google Scholar
• Qu N, Xu M, Mizoguchi I, et al. Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin Develop Immunol. 2013;2013:968549. PubMed PMID: 23956763. Pubmed Central PMCID: 3728507
   PubMed Web of Science ®Google Scholar
• Pene J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol. 2008;180:7423–30. PubMed PMID: 18490742
   PubMed Web of Science ®Google Scholar
• Yilmaz SB, Cicek N, Coskun M, et al. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012;304:465–9. PubMed PMID: 22426986
   PubMed Web of Science ®Google Scholar
• Kagami S, Rizzo HL, Lee JJ, et al. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Investigat Dermatol. 2010;130:1373–83. PubMed PMID: 20032993. PubMed Central PMCID: 2892169
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA dermatology. 2013 Oct;149(10):1180–5. PubMed PMID: 23945732
   Google Scholar
• Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52–72. PubMed PMID: 20926833
   Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Brit J Dermatol. 2013;168:412–21. PubMed PMID: 23106107
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Brit J Dermatol. 2013;168:402–11. PubMed PMID: 23362969
   PubMed Web of Science ®Google Scholar
• Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. New Engl J Med. 2012;366:1190–9. PubMed PMID: 22455413
   PubMed Web of Science ®Google Scholar
• Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheumat 2010;62:929–39. PubMed PMID: 20131262
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. New Engl J Med. 2012;366:1181–9. PubMed PMID: 22455412
   PubMed Web of Science ®Google Scholar
• Gaffen SL. Structure and signalling in the IL-17 receptor family. Nature Rev Immunol. 2009;9:556–67. PubMed PMID: 19575028. Pubmed Central PMCID: 2821718
   PubMed Web of Science ®Google Scholar
• Wright JF, Bennett F, Li B, et al. The human IL-17F/IL-17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J Immunol. 2008;181:2799–805. PubMed PMID: 18684971
   PubMed Web of Science ®Google Scholar
• Wright JF, Guo Y, Quazi A, et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem. 2007;282:13447–55. PubMed PMID: 17355969
   PubMed Web of Science ®Google Scholar
• Smith E, Stark MA, Zarbock A, et al. IL-17A inhibits the expansion of IL-17A-producing T cells in mice through “short-loop” inhibition via IL-17 receptor. J Immunol. 2008;181:1357–64. PubMed PMID: 18606690. PubMed Central PMCID: 2586908
   PubMed Web of Science ®Google Scholar
• von Vietinghoff S, Ley K. IL-17A controls IL-17F production and maintains blood neutrophil counts in mice. J Immunol. 2009;183:865–73. PubMed PMID: 19542376. Pubmed Central PMCID: 2759196
   PubMed Web of Science ®Google Scholar
• Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148:1244–50. PubMed PMID: 22911151
   PubMed Web of Science ®Google Scholar
• Puig L. Cardiovascular risk and psoriasis: the role of biologic therapy. [Riesgo cardiovascular y psoriasis: papel de la terapia biologica.] Actas Dermo-Sifiliograficas. 2012;103:853–62. PubMed PMID: 22591655
   Google Scholar
• de Boer OJ, van der Meer JJ, Teeling P, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol. 2010;220:499–508. PubMed PMID: 20020510
   PubMed Web of Science ®Google Scholar
• Csiszar A, Ungvari Z. Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease. Med–Hypotheses. 2004;63:696-8. PubMed PMID: 15325020
   PubMed Web of Science ®Google Scholar
• Cheng X, Yu X, Ding YJ, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008;127:89–97. PubMed PMID: 18294918
   PubMed Web of Science ®Google Scholar
• Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coronary Artery Dis. 2006;17:699–706. PubMed PMID: 17119379
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Raychaudhuri SK, Genovese MC. IL-17 receptor and its functional significance in psoriatic arthritis. Molec Cellular Biochem. 2012;359:419–29. PubMed PMID: 21894442
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol. 2013;44:183–93. PubMed PMID: 22362575
   PubMed Web of Science ®Google Scholar
• Gan EY, Chong WS, Tey HL. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. BioDrugs: Clin Immunother Biopharm Gene Ther. 2013;27:359–73. PubMed PMID: 23580094
   Google Scholar
• McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Annals of the rheumatic diseases. 2013 Jan 29. PubMed PMID: 23361084
   Google Scholar